Literature DB >> 17634230

A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia.

Qiliang Cai1, Masanao Murakami, Huaxin Si, Erle S Robertson.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) is a ubiquitously expressed transcriptional regulator involved in induction of numerous genes associated with angiogenesis and tumor growth. Kaposi's sarcoma, associated with increased angiogenesis, is a highly vascularized, endothelial cell-derived tumor. Previously, we have shown that the latency-associated nuclear antigen (LANA) encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) targets the HIF-1alpha suppressors von Hippel-Lindau protein and p53 for degradation via its suppressor of cytokine signaling-box motif, which recruits the EC5S ubiquitin complex. Here we further show that HIF-1alpha was aberrantly accumulated in KSHV latently infected primary effusion lymphoma (PEL) cells, as well as HEK293 cells infected with KSHV, and also show that a potential alpha-helical amino-terminal domain of LANA was important for HIF-1alpha nuclear accumulation in normoxic conditions. Moreover, we have now determined that this association was dependent on the residues 46 to 89 of LANA and the oxygen-dependent degradation domain of HIF-1alpha. Introduction of specific small interfering RNA against LANA into PEL cells also resulted in a diminished nuclear accumulation of HIF-1alpha. Therefore, these data show that LANA can function not only as an inhibitor of HIF-1alpha suppressor proteins but can also induce nuclear accumulation of HIF-1alpha during KSHV latent infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634230      PMCID: PMC2045494          DOI: 10.1128/JVI.00611-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions.

Authors:  Qiliang Cai; Ke Lan; Subhash C Verma; Huaxin Si; Doug Lin; Erle S Robertson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function.

Authors:  Huaxin Si; Erle S Robertson
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Physical and functional interactions between STAT3 and Kaposi's sarcoma-associated herpesvirus-encoded LANA.

Authors:  Ryuta Muromoto; Kanako Okabe; Masahiro Fujimuro; Kenji Sugiyama; Hideyoshi Yokosawa; Tsukasa Seya; Tadashi Matsuda
Journal:  FEBS Lett       Date:  2005-12-06       Impact factor: 4.124

4.  Does this have a familiar RING?

Authors:  A J Saurin; K L Borden; M N Boddy; P S Freemont
Journal:  Trends Biochem Sci       Date:  1996-06       Impact factor: 13.807

5.  Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors.

Authors:  Patrick A Carroll; Heidi L Kenerson; Raymond S Yeung; Michael Lagunoff
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

6.  Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.

Authors:  G Miller; L Heston; E Grogan; L Gradoville; M Rigsby; R Sun; D Shedd; V M Kushnaryov; S Grossberg; Y Chang
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

Authors:  K A Staskus; W Zhong; K Gebhard; B Herndier; H Wang; R Renne; J Beneke; J Pudney; D J Anderson; D Ganem; A T Haase
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus activation of vascular endothelial growth factor receptor 3 alters endothelial function and enhances infection.

Authors:  Xuefeng Zhang; Jian Feng Wang; Bala Chandran; Kris Persaud; Bronislaw Pytowski; Joyce Fingeroth; Jerome E Groopman
Journal:  J Biol Chem       Date:  2005-05-04       Impact factor: 5.157

9.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors.

Authors:  Qi-Liang Cai; Jason S Knight; Suhbash C Verma; Philip Zald; Erle S Robertson
Journal:  PLoS Pathog       Date:  2006-10       Impact factor: 6.823

View more
  49 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

2.  Characterization of the interaction between latency-associated nuclear antigen and glycogen synthase kinase 3beta.

Authors:  Thilo Hagen
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

Review 3.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

Review 4.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

5.  A compendium of proteins that interact with HIF-1α.

Authors:  Gregg L Semenza
Journal:  Exp Cell Res       Date:  2017-03-20       Impact factor: 3.905

6.  Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.

Authors:  Thomas S Uldrick; Kathleen M Wyvill; Pallavi Kumar; Deirdre O'Mahony; Wendy Bernstein; Karen Aleman; Mark N Polizzotto; Seth M Steinberg; Stefania Pittaluga; Vickie Marshall; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

7.  The Kaposi's Sarcoma-Associated Herpesvirus ORF34 Protein Interacts and Stabilizes HIF-2α via Binding to the HIF-2α bHLH and PAS Domains.

Authors:  Muzammel Haque; K G Kousoulas
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

8.  Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.

Authors:  Qiliang Cai; Suhbash C Verma; Pankaj Kumar; Michelle Ma; Erle S Robertson
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

9.  X-box binding protein 1 contributes to induction of the Kaposi's sarcoma-associated herpesvirus lytic cycle under hypoxic conditions.

Authors:  Lucy Dalton-Griffin; Sam J Wilson; Paul Kellam
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

10.  Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.

Authors:  Qiliang Cai; Erle S Robertson
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.